Engineering improved technology for nanoparticle-based adjuvant manufacture (2015–2018)
Over the next decade nanotechnology will redefine vaccines for animal and human health. Nanoparticle adjuvants will boost engineered vaccines that use minimal antigens such as recombinant proteins and synthetic peptides. This project will develop a platform technology for making and controlling the properties of inulin nanoparticles by optimising the engineering and manufacturing aspects of inulin nanoparticles to fundamentally understand the relationship between physical-chemical properties and efficacy. Completion of this project will produce potent nanoparticle-based adjuvants underpinned by novel manufacturing technology, to ultimately facilitate the development of more effective and protective vaccines for animals and humans.